...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology research: the official journal of the Japan Society of Hepatology >Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching
【24h】

Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching

机译：安全性和有效性的lenvatinib老人患者不可切除的肝细胞癌:多中心与倾向分析分数匹配

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim Lenvatinib has become available as first‐line therapy for patients with unresectable hepatocellular carcinoma (HCC). However, the safety and efficacy of lenvatinib in elderly patients with HCC has not been sufficiently investigated. We compared the frequency of adverse events and prognosis between elderly and non‐elderly patients with HCC who received lenvatinib. Methods A total of 100 patients with HCC who received lenvatinib were selected using propensity score matching: 50 patients were elderly (age ≥75?years) and 50 patients were non‐elderly. Results In the elderly group, 20% of patients experienced fatigue (36.0%), decreased appetite (26.0%), hypothyroidism (24.0%), proteinuria (22.0%), palmar‐plantar erythrodysesthesia (22.0%), and hypertension (20.0%) of any grade as treatment‐related adverse events. In addition, 10% of patients experienced grade?≥3 treatment‐related fatigue (12.0%). In the non‐elderly group, 20% of patients experienced palmar‐plantar erythrodysesthesia (42.0%), fatigue (28.0%), decreased appetite (22.0%), and diarrhea (20.0%) of any grade as treatment‐related adverse events. In addition, 10% of patients experienced grade?≥3 treatment‐related proteinuria (10.0%). There were no significant differences between the elderly and non‐elderly groups in the frequency of adverse events. Regarding overall and progression‐free survival, there were no significant differences between the elderly and non‐elderly groups (hazard ratio 0.972, 95% confidence interval 0.374–2.529; and hazard ratio 1.362, 95% confidence interval 0.687–2.700, respectively). Palmar‐plantar erythrodysesthesia (hazard ratio 0.117, 95% confidence interval 0.015–0.916) was independently associated with overall survival in a multivariate analysis. Conclusions Lenvatinib can be used safely and efficaciously regardless of age in patients with HCC.
机译：目的Lenvatinib已经成为可用的第一线治疗不可切除的患者肝细胞癌(HCC)。安全性和有效性的lenvatinib老人肝癌患者并不充分调查。老年人和之间的不良事件和预后非老年患者与肝细胞癌接受lenvatinib。肝细胞癌接受lenvatinib选择使用倾向得分匹配:50个病人老年人(年龄≥75岁?年)和50例非老年人。在20%的病人经历过疲劳(36.0%),食欲下降(26.0%),甲状腺机能减退erythrodysesthesia(22.0%)和高血压(20.0%)的任何年级的治疗相关的不良事件。经历过级?(12.0%)。患者手掌的足底食欲下降(22.0%)、腹泻(20.0%)任何年级的治疗相关的不良事件。此外,在10%的病人有经验年级吗?没有显著的差异老年人和非老年群体在频的不良事件。发展高自由生存在没有老年人和之间的显著差异非老年人组(危害比为0.972,95%置信区间0.374 - -2.529;1.362, 95%置信区间0.687 - -2.700,分别)。(危险比为0.117,95%置信区间0.015 - -0.916)是独立相关在多变量分析整体存活率。结论Lenvatinib可以安全使用有效地不管年龄患者HCC。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号